read the whole article but a bit underwhelming in my view. a missed opportunity to promote the company a bit more
the article mispresented that neuren is looking for financing option to commercialize PMS. The company is in fact fully funded to take it all the way to FDA approval. There's no mention of the strength of the cash position
no mention of the consensus valuation (ie north of $25)
no mention of the other new indications in the works
no mention of how the PMS end point agreement would benefit the upcoming Pitt Hopkins phase 3 discussion
no mention of how Neuren could potentially be the first to provide treatment for PMS and Pitt Hopkins
read the whole article but a bit underwhelming in my view. a...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.92 |
Change
0.070(0.54%) |
Mkt cap ! $1.607B | |||
| Open | High | Low | Value | Volume |
| $13.15 | $13.37 | $12.85 | $8.049M | 616.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4175 | $12.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.03 | 100 | 1 |
View Market Depth
| Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |